PURPOSE: To examine the effect of lymph node dissection on the outcomes of patients who underwent salvage radical prostatectomy (SRP). MATERIAL AND METHODS: We retrospectively reviewed data from radiation-recurrent patients with prostate cancer (PCa) who underwent SRP from 2000-2016. None of the patients had clinical lymph node involvement before SRP. The effect of the number of removed lymph nodes (RLNs) and the number of positive lymph nodes (PLNs) on biochemical recurrence (BCR)-free survival, metastases free survival, and overall survival (OS) was tested in multivariable Cox regression analyses. RESULTS: About 334 patients underwent SRP and pelvic lymph node dissection (PLND). Lymph node involvement was associated with increased risk of BCR (p < .001), metastasis (p < .001), and overall mortality (p = .006). In a multivariable Cox regression analysis, an increased number of RLNs significantly lowered the risk of BCR (hazard ratio [HR] 0.96, p = .01). In patients with positive lymph nodes, a higher number of RLNs and a lower number of PLNs were associated with improved freedom from BCR (HR 0.89, p = .001 and HR 1.34, p = .008, respectively). At a median follow-up of 23.9 months (interquartile range, 4.7-37.7), neither the number of RLNs nor the number of PLNs were associated with OS (p = .69 and p = .34, respectively). CONCLUSION: Pathologic lymph node involvement increased the risk of BCR, metastasis and overall mortality in radiation-recurrent PCa patients undergoing SRP. The risk of BCR decreased steadily with a higher number of RLNs during SRP. Further research is needed to support this conclusion and develop a precise therapeutic adjuvant strategy based on the number of RLNs and PLNs.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology King Faisal Medical City Abha Saudi Arabia

Department of Urology Medical University of Silesia Zabrze Poland

Department of Urology Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences Okayama Japan

Department of Urology Rennes University Hospital Rennes France

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital Cologne Cologne Germany

Department of Urology University Hospital Zurich Zurich Switzerland

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Vita Salute San Raffaele University Milan Italy

Department of Urology Weill Cornell Medical College New York City New York USA

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Division of Urology Department of Surgical Sciences San Giovanni Battista Hospital University of Studies of Torino Turin Italy

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Men's Health and Reproductive Health Research Center Shahid Beheshti University of Medical Sciences Tehran Iran

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

Zobrazit více v PubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin. 2020. PubMed

Ahallal Y, Shariat SF, Chade DC, et al. Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. BJU Int. 2011;108(5):724‐728. PubMed PMC

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112(2):307‐314. PubMed

Kuban DA, Thames HD, Levy LB, et al. Long‐term multi‐institutional analysis of stage T1‐T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57(4):915‐928. PubMed

Lughezzani G, Briganti A, Karakiewicz PI, et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58(5):687‐700. PubMed PMC

Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5(10):1555‐1584. PubMed PMC

Chun FK, Briganti A, Shariat SF, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 2006;98(2):329‐334. PubMed

Lee WR, Hanks GE, Hanlon A. Increasing prostate‐specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997;15(1):230‐238. PubMed

Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation‐recurrent prostate cancer: a multi‐institutional collaboration. Eur Urol. 2011;60(2):205‐210. PubMed PMC

Heidenreich A, Richter S, Thüer D, Pfister D. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st‐century radiotherapy. Eur Urol. 2010;57(3):437‐445. PubMed

Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation‐recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012;61(5):961‐971. PubMed

Grossfeld GD, Li YP, PL DP, Carroll PR. Patterns of failure after primary local therapy for prostate cancer and rationale for secondary therapy. Urology. 2002;60(3 Suppl 1):57‐62. PubMed

Pontes JE, Montie J, Klein E, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer. 1993;71(S3):976‐980. PubMed

Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5‐year followup. J Urol. 1998;159(3):950‐954. PubMed

RoachM, 3rd, Hanks G, Thames H, Jr., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965‐974. PubMed

Quhal F, Pradere B, Sari Motlagh R, et al. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer [published online ahead of print September 29, 2020]. Minerva Urol Nefrol. 2020. 10.23736/s0393-2249.20.03938-7 PubMed DOI

Quhal F, Abufaraj M, Janisch F, et al. The significance of De Ritis ratio in patients with radiation‐recurrent prostate cancer undergoing salvage radical prostatectomy. Arab. J Urol. 2020:1‐6. PubMed PMC

Vartolomei MD, D'Andrea D, Chade DC, et al. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncol: Semin Orig Investig. 2019;37(2):123‐129. PubMed

Mari A, Abufaraj M, Foerster B, et al. Oncologic effect of cumulative smoking exposure in patients treated with salvage radical prostatectomy for radiation‐recurrent prostate cancer. Clin Genitourin Cancer. 2018;16(3):e619‐e627. PubMed

Abdollah F, Gandaglia G, Suardi N, et al. More extensive pelvic lymph node dissection improves survival in patients with node‐positive prostate cancer. Eur Urol. 2015;67(2):212‐219. PubMed

Abdollah F, Karnes RJ, Suardi N, et al. Predicting survival of patients with node‐positive prostate cancer following multimodal treatment. Eur Urol. 2014;65(3):554‐562. PubMed

Boorjian SA, Thompson RH, Siddiqui S, et al. Long‐term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178(3 Pt 1):864‐870. PubMed

Marra G, Valerio M, Heidegger I, et al. Management of patients with node‐positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review. Eur Urol Oncol. 2020;3(5):565‐581. PubMed

Pokala N, Huynh DL, Henderson AA, Johans C. Survival outcomes in men undergoing radical prostatectomy after primary radiation treatment for adenocarcinoma of the prostate. Clin Genitourin Cancer. 2016;14(3):218‐225. PubMed

Wenzel M, Würnschimmel C, Nocera L, et al. The effect of lymph node dissection on cancer‐specific survival in salvage radical prostatectomy patients. Prostate. 2021;81(6):339‐346. PubMed

Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967‐987. PubMed

Yamazaki H, Masui K, Suzuki G, et al. Effect of androgen deprivation therapy on other‐cause of mortality in elderly patients with clinically localized prostate cancer treated with modern radiotherapy: is there a negative impact? J Clin Med. 2019;8(3):338. PubMed PMC

Briganti A, Chun FKH, Salonia A, et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology. 2007;69(1):147‐151. PubMed

Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: a population‐based analysis. Prostate. 2014;74(2):210‐216. PubMed

Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life‐expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100(6):1254‐1258. PubMed

Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA Ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res. 2018;24(24):6300‐6307. PubMed

Fossati N, Scarcella S, Gandaglia G, et al. Underestimation of positron emission tomography/computerized tomography in assessing tumor burden in prostate cancer nodal recurrence: head‐to‐head comparison of (68)Ga‐PSMA and (11)C‐choline in a large, multi‐institutional series of extended salvage lymph node dissections. J Urol. 2020;204(2):296‐302. PubMed

Abufaraj M, Grubmüller B, Zeitlinger M, et al. Prospective evaluation of the performance of [(68)Ga]Ga‐PSMA‐11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(10):2169‐2177. PubMed PMC

Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA‐HBED‐CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43(3):397‐403. PubMed

Pfister D, Haidl F, Nestler T, et al. 68) Ga‐PSMA‐PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. BJU Int. 2020;126(6):679‐683. PubMed